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Traumatic brain injury is a multifarious damage with a broad spectrum of symptoms and 
disabilities. Due to the limited capacity of the central nervous system to repair traumatic injuries 
and the secondary cascade of insults that lead to worsened neurologic dysfunction, nowadays no 
treatment is able to effectively restore brain tissue. Research has been focusing on the stimulation 
of endogenous neural stem cells to viably and functionally repopulates the injured parenchyma as 
possible treatment for brain injury. Lipoic acid (LA) has been demonstrated being a potent 
antioxidant promoting neuro-regeneration and angiogenesis. Thus, the aim of this study was to 
develop and assesses the reparative potential of a polymeric scaffold designed for brain tissue 
repair in combination with lipoic acid.   
Adult Wistar rats were subjected to cryogenic traumatic brain injury. A channelled-porous 
scaffold was created using a copolymer of ethyl acrylate and hydroxyethylacrylate, p(EA-co-
HEA). This was grafted into cerebral penumbra alone or combined with intraperitoneal LA 
administration as a new regenerative strategy. Histological and cytological evaluation was 
performed after 15 and 60 days  and structural magnetic resonance (MRI) assessment was also 
performed at 2 and 6 months after the surgery. The results obtained suggest that this strategy 
promotes neuron migration and new blood vessels formation. The scaffold resulted colonised by a 
high number of mature cells and decreased microglial response, in particular when administrated 
with LA.  
These evidences demonstrated that the combination of a channelled polymer scaffold with a 
pharmacological treatment using LA may represent a potential treatment for neural tissue repair 
after brain injury. 
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 1. INTRODUCTION 
Traumatic brain injury (TBI) is a serious health problem around the world [1]. A significant 
number of patients with TBI survive with considerable brain damage and behavioural disability, 
even after mild or moderate brain injury [2-5]. Subsequent to primary injury, a neuroinflammatory 
response characterised by the release of reactive oxygen species (ROSs) from neutrophils are 
responsible for a secondary deleterious phenomena [6-8] due to increase of local oxidative stress 
and consequent cells death [9-12]. In our previous studies, it was shown how systemic 
administration of antioxidants, such as lipoic acid (LA), favours healing brain processes. In this 
sense, we observed that LA was able to recover the damaged tissue after brain injury model in rats 
via increasing the antioxidant aptitude of the tissue, promote angiogenesis and decrease the glial 
response [13, 14]. 
During the last decade, the use of bioactive materials with regenerative aptitude has been 
extensively adopted in the field of biomedicine [15, 16]. Moreover, the application of natural and 
synthetic biopolymers has been widely used in clinical and experimental cases such as wound 
healing, drug delivery systems, vascular grafts and or tissue regeneration [17, 18]. 
Recently, different biogenic matrices have been developed as biocompatible/bioinductive 
scaffolds able to create a favourable environment for the regeneration of the nervous system and in 
particular for neural cells; the fibronectin as well as collagen matrices have been shown to 
promote nerve regeneration [19-22]. 
However, synthetic polymers have been proposed as a suitable alternative choice to natural 
molecules due to their versatility. Indeed, polymers can be developed with a wide variety of 
compounds (e.g. polystyrene, nylon, fibrinogen, collagen, hydrogels.) and they can be modified to 
achieve distinct physic-chemical and biomimetic properties [17, 18, 23, 24]. 
Soria and collaborators [24] have previously shown in vitro how biopolymers based on a  
combination of ethyl acrylate (EA) and hydroxyethylacrylate (HEA) may represent  a suitable 
substrate for proliferation and differentiation of rodent NSCs [23, 25]; these were also tested for 
neuro-regenerative purposes in the CNS showing promising results [25]. 
We hypothesize that the administration of lipoic acid in combination with the p(EA-co-HEA) 
scaffold after brain injury can increase the neuroregenerative capacity of the tissue. There is no 
previous study on the neuro-regenerative ability of a scaffold of p(EA-co-HEA) when applied in 
combination with systemic administration of lipoic acid. Thus, this study aimed at developing and 
assesses the reparative potential of a polymeric p(EA-co-HEA) scaffold designed for brain tissue 
repair in rats treated with systemic therapy with lipoic acid.  
.  
 
2. MATERIALS AND METHODS 
 
2.1 Substrate material preparation 
Scaffolds were prepared following a porogen-template leaching method, as described in [25-
27]. The porous structure was generated with a template of sintered Nylon fabrics (Saati SA, 
Barcelona, Spain) of nominal thread diameter of 80 microns and mesh opening of 120 microns, 
which was afterwards eliminated by dissolution. The polymer matrix was a copolymer of ethyl 
acrylate (EA, 99% pure, Sigma-Aldrich, Spain) and hydroxyethyl acrylate (HEA, 99% pure, 
Sigma-Aldrich,) with EA:HEA mass ratio of 9:1, cross-linked into a network with ethyleneglycol 
dimethacrylate (EGDMA, 98% pure, Sigma-Aldrich) in a mass ratio of (EA+HEA):EGDMA = 
99:1. Azo-bis-isobutyronitrile (AIBN, 98% pure. Merck) was also added (0.01 wt%) to act as 
thermal initiator of the polymerization. The polymerization was carried out for 24 h at 60ºC, and 
for 24 h more at 90ºC in specific moulds (5 x 10 cm). Subsequent to the polymerisation reaction, 
all the templates were dissolved by washing in nitric acid (65%, Scharlab, Spain) under gentle 
shaking for 48 h. Finally, the obtained materials were washed in boiling ethanol for 40 h, and 
dried 24 h at room temperature, a further 24 h under vacuum and room temperature, and 24 h 
more under vacuum at 60ºC. Beams of approximately 1 mm thick and with a length of 4 mm were 
cut with a stainless steel blade (Procter & Gamble, USA) and used in the experiments. All samples 
were sterilized with a 25 kGy dose of gamma irradiation in a 60Co source. 
 
2.2 Surgery and brain cryo-injury 
Adult male Wistar rats weighing 250 ± 25 g were purchased from Harlan (Italy) one week before 
starting the experiment. Rats were maintained in controlled conditions at temperature of (20 °C) 
and humidity of (60 %). They also received constant light-dark cycles of 12 hours and feed with 
water and food ad libitum. Handling and care of animals were done according to the “Real 
Decreto” 1201/05, supervised and approved by the Committee of Ethics and Experimental 
Procedures of the Universidad CEU-Cardenal Herrera. Rats were anesthetised by intraperitoneal 
injection (i.p.) with a mixture consisting of 12 mg/kg ketamine, (Imalgene, Leonvet, Spain), 0.4 
mg/kg acepromizine, (Calmo Neosan, Pfizer, Spain) and 0.02 mg/kg phentanil (Baxtel, USA) and 
then placed in a stereotaxic frame. The dorsal part of the skull was exposed and a hole was drilled 
(1.5 mm ø) on stereotaxic coordinates [28] antero-posterior: 0 mm from bregma and lateral: 1.5 
mm from medial line. The brain cryo-injury was performed following the protocol described by 
Quintana et al., [28]. Thus, the cryo-injury (4 mm deep) was performed in the cerebral cortex by 
using a stainless steel probe (1 mm of diameter) previously frozen in liquid nitrogen (-196 ºC). 
Buprenorphine (0.05 mg/kg, subcutaneously) was administered postoperatively and the rats were 
placed on heating pads at 37°C and monitored continuously for 2 h after surgery. In addition, 
immediately after surgery, all subjects received 3% body weight of 0.9% saline subcutaneously to 
prevent dehydration. 
 2.3 Lipoic acid administration 
Cryo-injured rats were randomly selected immediately after surgery. The first group (BM+LA) of 
samples (N = 28) received a daily intraperitoneal (i.p.) dose of lipoic acid 100 mg/kg (LA) (Sigma 
Aldrich) for 7 days starting the same day of surgery. The second group (BM) of samples (N = 28) 
received the same volume of saline (NaCl 0.9 % i.p.) for the same period of time. Control group 
consisted of animals that received no brain injury, kept under the same conditions of anaesthesia 
for the same period of time as in the experimental groups, but with no i.p. injection. 
 
2.4. Tissue preparation and experimental design  
Animals were sacrificed by using an overdose of sodium pentobarbital (Dolethal, Vetoquinol 
S.A.) via i.p. injection. Once sacrificed, animals were transcardially perfused with 100 mL of 
saline followed by 200 mL of 4 % paraformaldehyde (PFA) (Sigma-Aldrich, Spain) in saline 
phosphate buffer (PBS) 0.01 M pH 7.2. Brains were removed and post fixed in the same fixative 
solution for 24 h at 4 °C. Subsequently, all the extracted brains were cryo-protected by immersion 
in a PBS solution 0.01 M of sucrose (30%; pH 7.1) for five days at 4 °C. Sections of 25 μm thick 
were serially obtained with a cryostat (Leica) and mounted onto glass slides. Sections were stored 
at -80 °C until use. 
The experimental design of this study was to perform histological and cytological evaluation 15 
and 60 days after the surgery (n = 8 for each group). Moreover, an ultra-structural study was also 
carried out through magnetic resonance imaging (MRI) at 2 and 6 months after the surgery (n = 6 
for each group). 
 
 
2.5. Histological staining and microscopy  
Haematoxylin-eosin staining was performed for histological assessment of the injured area and the 
insertion of the biomaterial. Sections were rinsed with PBS 0.01 M for 5 min, and then dehydrated 
with increasing ethanol for 3 min (100º, 96º, 70º, 50º, 30º) and finally rinsed with bi-distilled 
water for 3 min. After incubation in Harris haematoxylin (Sigma Aldrich, Spain) for 5 min, the 
specimens were washed with water and placed in 1 % HCl - EtOH 70º for 5 sec; they were rinsed 
with water for further 5 min. Afterwards, these specimens were incubated in a 2 % eosin aqueous 
solution (Sigma Aldrich, Spain) for 2 min, dehydrated with ethanol 96º and 100º and finally 
cover-slipped with Eukitt® (Sigma Aldrich). Digital images were acquired with a Nikon DS-Fi-1 
digital camera (Barcelona, Spain) coupled to a Leica DM2000 Microscope at 5x, 20x, 40x and 63x 
magnifications.  
 
2.6. Immunofluorescence staining and confocal microscopy  
Further sections were obtained from the injury and rinsed three times using a 0.01 M PBS solution 
for 5 min. The specimens were first immersed in 0.1 % PBS–Triton containing 20 % Foetal 
Bovine Serum (Gibco®, Life TechnologiesTM) for 2 hours and then incubated at 4 °C overnight 
with primary antibodies: anti-Collagen IV (1:200, Abcam, Spain); anti-Glial Fibrilar Acidic 
Protein [GFAP] (1:500, Dako Cytomation, Denmark), anti-CD68 [ED1]  (1:200, Chemicon, UK), 
anti-Iba1 (1:200, Wako, German), anti-beta III tubulin [Tuj1] (1:200, Abcam, Spain) and anti-
microtubule associated protein 2 [MAP2] (1:200, Millipore, Spain). 
Secondary antibodies Alexa Fluor® 488 IgG (H+L) (1:200, Invitrogen, Spain) and Alexa Fluor® 
555 IgG (H+L) (1:200, Invitrogen, Spain) were used for further 2 h of incubation at room 
temperature in the darkness. Afterwards, sections were mounted with DAPI Vectashield (Vector 
Laboratories, UK) and image-processed using a Leica DM2000 Microscope at 5x magnification 
and a Nikon EZ-C1 in Ti-U Eclipse Inverted Confocal Microscope (Tokyo, Japan) using 40x and 
63x oil objectives (Plan Apo, Nikon).  
 
2.7. Magnetic Resonance Imaging Study 
The structural study of animals was carried out through Magnetic Resonance Imaging (MRI) 
7.0T-T BioSpec 70/30 horizontal scanner (Bruker BioSpin, Ettlingen, Germany), equipped with an 
actively shielded gradient system (400mT/mm 12 cm inner diameter). The receiver coil was a 4-
cannel phased-array surface coil for the rat brain. Animals were placed in supine position in a 
Plexiglas holder with a nose cone for administering anaesthetic gases (1.5% isofluorane in a 
mixture of 30% O2 and 70% CO2) and were fixed using a tooth bar, ear bars and adhesive tape. 
Tripilot scans were used to ensure accurate positioning of the head in the isocenter of the magnet. 
Brain lesions were evaluated by T2 mapping of coronal slices acquired with a multislice-multi-
echo (MSME) sequence by applying 16 TEs, from 11 to 176 ms, TR = 4764 ms, slice thickness = 
1 mm, number of slices = 18, FOV = 40 x 40 mm, and matrix size = 256 x 256 pixels, resulting in 
a spatial resolution of 0.156 x 0.156 mm in 1.00 mm slice thickness. At the end of the procedure, 
the animals were removed from the platform ad and woken up with an i.p. injection (1 mg/kg) of 
atipamezole (Antisedan®, Pfizer, Spain). 
 
2.8. Quantification and Statistical Analysis 
Immunocytochemical images were analysed with Image J 1.44i for Mac. The quantifications were 
performed using four sections of each animal (n = 8 for each group). Three images in each section 
were randomly acquired inside the biomaterial and quantified. The density of cells (nº cells/mm2) 
was assessed by counting the number of nuclei (determined by DAPI staining) co-expressing the 
marker to analyse. The percentage of area occupied by astrocytes and blood vessels was also 
calculated as the area occupied by the corresponding marker referred to total area quantified. 
Images were converted to binary after thresholding and the area calculation was set in 
measurements.  
The T2 maps images were reconstructed with ParaVision 5.03 software (Bruker BioSpin, 
Ettlingen, Germany) and analysed with the program ImageJ 1.44f for Mac to obtain the grey 
values inside the biomaterial tissue. To do so, images were assigned predetermined values (20-
130) and grey values were set in measurements. 
To perform the statistical analyses of the data, GraphPad Prism 4 for Mac was used. Statistical 
significances were assessed by two-way ANOVA followed by Bonferronni post-test. Data are 
represented as means ± standard deviation, and differences are considered significant at p < 0.05. 
 
3. RESULTS 
3.1. Biocompatibility of the polymeric scaffold  
The biomaterial tested in this study was successfully implanted close to the LV as previously 
described (Fig. 1A). No immunological rejection was observed. Indeed a perfect biocompatibility 
with the surrounding tissue and a sound healthy interface between the brain tissue and the 
biomaterial were observed (Fig. 1B). In addition, the SVZ integrity was not perturbed by the 
insertion of the scaffold (Fig. 1C). One of the first remarkable findings was the presence of a high 
number of cells inside the biomaterial (Fig. 1D). Specifically, the animal specimens treated with 
LA presented greater cytoplasmic expansions (Fig. 2A). The cell population within the 
biomaterial, (Fig. 2B) showed no significant increase compared to the control group (p < 0.001 
and p < 0.01 for BM and BM+LA respectively) 15 days after brain injury. However at 60 days, 
the specimens treated with LA presented a cell density comparable to that of the control 
specimens. However, this increase in cell density was not observed in the specimens that were not 
treated with LA (p < 0.001 vs Control). 
 
3.2. New blood vessels are generated inside the biomaterial  
The immunofluorescence study for blood vessels (Collagen IV+) showed the presence of blood 
vessels formation inside the biomaterial (Fig. 3A) characterised by a correct morphology and 
functionality (Fig. 3B).  
Concerning the quantification of the endothelial cell density (Fig. 3C) at 15 days, the animal 
specimens treated with LA presented a significant increase in the number of endothelial cells 
compared to non-treated animals (p < 0.05). However, after 60 days the cell density was increased 
in both experimental groups (p < 0.01).  
Furthermore, the area occupied by blood vessels (Fig. 3D) in both experimental groups was 
comparable with control group at 15 days. However, an increase of area was found in both 
experimental groups at 60 days. Interestingly, LA-treated specimens showed a higher area 
compared to untreated specimens (p < 0.01). 
 
3.3. Astrocytes grow inside the polymeric scaffold   
The immunofluorescences analysis of the astrocytes (GFAP+ cells) (Fig. 4A) showed a rare 
presence of astrocytes in untreated animals at 15 days, while the LA treated animals showed an 
ample growth of astrocytes inside the biomaterial.  However, an abundant number of astrocytes 
was observed in both experimental groups at 60 days. 
The quantitative analysis showed an increase in the density of GFAP+ cells (Fig. 4B) only in 
LA treated animals compared to the control at both times (p < 0.05 at 15 days and p < 0.01 at 60 
days). Conversely, the measurement of the area occupied by astrocytes (Fig. 4C) showed a 
statistical significant increase in LA treated group compared to the untreated group (p < 0.001) 
and even more compare to the control group (p < 0.001) at 15 days. However, at 60 days, the area 
of astrocytes was increased in both experimental groups compared to the control specimens (p < 
0.01). 
 3.4. Presence of microglial cells  
The presence of microgial cells and their morphology are crucial for the determination of the 
inflammatory response. Therefore, the immunofluorescences analysis for microglia (Iba1+ cells) 
and activated microglia/macrophage (ED1+ cells) highlighted a high number of microglial cells 
inside the biomaterial in both experimental groups at 15 days with a decrease at 60 days (Fig. 5). 
The quantification of the density of Iba1+ cells (Fig. 6A) showed a significant increase in both 
experimental groups compared to the control but not between experimental groups. 
The quantification of activated microglia/macrophages (ED1+ cells) (Fig. 6B) showed a 
significant increase in both experimental groups compared to the control at all time points (p < 
0.001). Interestingly, at 15 days, ED1+ cells showed a decrease in LA treated group compared to 
the untreated group (p < 0.01). 
Resting microglia, identified as Iba1+ED1- cells (Fig. 6C), showed a decrease at 60 days in La-
treated group compared with the untreated group (p < 0.001). 
Infiltrated macrophages were identified as Iba1-ED1+ (Fig. 6D). An increase in infiltrated 
macrophages was found at all time points and specially in untreated animals at 60 days.  
Activated microglia, identified by Iba1+ED1+ cells (Fig. 6E), was increased in a similar way to 
that observed with infiltrated macrophages. In addition, LA administration decreased activated 
microglia in a significant way compared with untreated group (p < 0.05).  
 
3.5. Neuronal bodies and axons are found inside the biomaterial 
The presence of young neurons was identified by immunofluorescence for the marker Tuj1 
(red) and MAP2 (green) was used in order to identify mature neurons (Fig. 8). Axons extending 
from the surrounding tissue into the biomaterial were observed 60 days after the brain injury (Fig. 
7A). In addition, immature neurons (Tuj1+ cells) inside the biomaterial expressing as well the 
marker MAP2 were detected (Fig. 7B). Mature neurons (Fig. 7C) and their axons were visible 
inside the biomaterial (Fig. 8D). 
Quantifications developed 60 days after the brain injury (Fig. 7E) showed an increase of 
immature neurons after LA treatment compared with untreated group (p < 0.05).  In addition, the 
density of mature neurons was significantly increased after LA treatment compared to untreated 
group (p < 0.001) and decreased in untreated animals compared with control group (p < 0.001). 
 
3.6. MRI: quantification of the healthy neural tissue inside the biomaterial 
The structural analysis performed using magnetic resonance imaging shows the presence of 
liquid and the health state of the neural tissue that could be quantified in grey-scale values. T2 
scans through MRI in untreated animals (Fig. 8A) and LA treated animals (Fig. 8B) were carried 
out at 2 and 6 months after brain injury. The quantification of the grey values inside the 
biomaterial (Fig. 8C) showed a significant decrease of grey values in both experimental groups (p 
< 0.001) indicating a high presence of liquid inside the biomaterial. However, it was also observed 
a significant increase of grey values in LA-treated group compared untreated group (p < 0.001) 6 
months after brain injury; associated with tissue regeneration. 
 
4. DISCUSSION 
Brain injury is a devastating phenomenon with no effective treatment available for the time 
being. Due to the limited capacity of the brain to repair itself, the search of new neural repair 
strategies has been the goal standard in regenerative medicine in the last decades. The 
transplantation of rat or mouse stem/progenitor cells has been used recently in order to study the 
mechanisms of CNS regeneration. Some studies have reported that engrafted cells can survive in 
the host brain for up to a year [29, 30]. Nevertheless, in most of the cases only less than 2% of the 
transplanted cells engraft and additionally, most of the engrafted cells differentiate into glia, not 
neurons [31, 32]. However, the brain also has endogenous NSCs located in the dentate gyrus and 
the subventricular zone [33, 34]. Significant increases in cell proliferation and neurogenesis have 
been reported in the SVZ and DG in response to brain injury [35], suggesting that the brain has an 
inherent potential to restore itself. However this self-repair capacity is limited due to the 
exacerbated inflammatory response. Following traumatic brain injury, some studies have reported 
that several growth factors and drugs can enhance neurogenesis and improve functional recovery 
of the injured brain. For instance, it has been observed that administration of growth factors such 
as epidermal growth factor (EGF) or vascular endothelial growth factor (VEGF) –a potent 
angiogenic factor– can significantly enhance cell proliferation in the SVZ after trauma [36, 37]. 
An increase in angiogenesis has been observed when LA is combined with biomaterial application 
after brain injury. This result agrees with those previous reported by our group where systemic 
administration of LA can stimulate angiogenesis and proliferation after brain injury [14].  
The use of polymer scaffolds has been recently developed and applied in central and peripheral 
nervous system as an attempt to favour cell support in regeneration. The development and design 
of synthetic extracellular matrix have been the main goal in tissue engineering in order to regulate 
cell behaviour and tissue progression in regeneration. The sought properties for nerve regeneration 
concerning biomaterials are less inflammatory response, adequate porosity for vascularization and 
cell migration, biocompatibility with the tissue and three-dimensional matrices with appropriate 
mechanical properties to mimic extracellular matrix [38, 39]. Previously in vitro studies developed 
by our group has shown these scaffolds based on p(EA-co-HEA) as a suitable substrates for 
proliferation and differentiation of rodent NSCs [23, 24]. The recent findings exposed above now 
suggest that this polymeric scaffold can be used for brain tissue repair after brain injury in vivo, 
acting as a suitable substrate for cell growth.  
After the primary brain injury, the secondary response including glial reaction promotes glial 
scar formation hinder tissue regeneration. We have previously reported a decrease in the glial scar 
formation and inflammation when LA was administered systemically after brain injury [13, 14]. In 
addition, the results obtained in this study suggest that the application of the p(EA-co-HEA) 
scaffold could be acting in the same way, reducing glial scarring and activated microglia through a 
decrease on inflammation. Similar results were obtained by Park et al. using a fibrous 
poly(glycolic acid) scaffold seeded with NSCs in a stroke model, showing that the cells were able 
to differentiate and reduce the inflammation and glial scarring [40]. An implant of a biomaterial 
based on poly(lactic-co-glycolic acid) (PLGA) and polylysine seeded with NSCs was used in a rat 
model of spinal cord injury [41]. The study showed an increase in the motor activity of the 
animals and a decrease in the glial scar formation. Interestingly, the improvements regarding the 
glial scar formation were attributed in part to the implant material itself. 
Concluding, we have reported that combined application of p(EA-co-HEA) 90/10 scaffold and 
LA administration promotes cell colonization of the damaged area and tissue regeneration. A 
decrease of the glial scarring as well as an increase of angiogenesis has been observed, in addition 
to an increase of neurons inside the biomaterial. This results open new insights into the 
regeneration strategies after brain injury. However, future interventions may include other 
strategies –such as in situ controlled delivery of neuroprotective substances or growth factors– in 




The use of p(EA-co-HEA) 90/10 polymeric scaffold provides good support for the 
regeneration of damaged tissue after brain injury. The application of the polymeric scaffold 
together with a systemic LA administration increases the angiogenesis, decreases glial scaring, 
and favour neuronal migration into the biomaterial. These results represent a step forward in the 
regenerative strategy for brain injury.  
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Figure 1. Histological characterisation of the implanted biomaterial and surrounding 
area shows the implantation of the scaffold and the colonization of cells.  
A.Haematoxylin-eosin staining of a brain coronal section with BM. B. Image of the area 
close to the LV showing the insertion of the biomaterial respecting the integrity of the LV. C. 
Higher magnificaton image showing the continuity between the neural tissue and the 
biomaterial. D. View of the scaffold showing a high density of cells. The edge of the 
biomaterial is delimited by the dotted line. BM: biomaterial, LV: lateral ventricle. Scale bars: 
500 μm in A, in B 100 μm and 500 μm in C and D. 
 
 Figure 2. Cells are able to colonize and grow inside the biomaterial.   
A. Images of the tissue inside the biomaterial where it is possible to appreciate a high 
number of cells and cytoplasmic extensions in LA treated animal. B. Cell density (nº 
cells/mm2) inside the biomaterial in the different experimental groups. BM: biomaterial, 
BM+LA: biomaterial and lipoic acid treatment. Scale bars: 200 μm and 50 μm in the 
expansions. . *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 Figure 3. Immunofluorescence for Collagen IV shows blood vessels formation inside 
the biomaterial.                                    
A. Immunofluorescence for collagen IV of blood vessels (red) inside the biomaterial at 15 
and 60 days. Dapi was used to identify nuclei and biomaterial position. B. Top: Magnification 
image of a blood vessel well formed. Bottom: Magnification of a haematoxylin-eosin staining 
showing the functionality of the blood vessel. Scale bars: 200 μm for A; 50 μm for Top and 
100 μm for Bottom in B. C. Quantification of collagen positive cell density (nº cells/mm2) 
inside the biomaterial. D. Quantification of area occupied by blood vessels (% area). Control: 
no injury or biomaterial, BM: biomaterial injured but untreated, BM+LA: injured, biomaterial 





Figure 4. Immunofluorescence for GFAP shows the presence of astrocytes inside the 
biomaterial.  
A. Immunofluorescence for GFAP was done to identify astrocytes (green) inside the 
biomaterial at 15 and 60 days. Dapi was used to identify nuclei and biomaterial position. Scale 
bars: 200 μm. B. The graph represents the quantification of the density (nº cells/mm2) of 
astroglial cells inside the biomaterial. C. Quantification of the area occupied by astrocytes (% 
area). Control: no injury or biomaterial, BM: biomaterial injured but untreated, BM+LA: 










Figure 5. Microglial response is activated 15 days after brain injury.  
Immunofluorescence for microglia cells (Iba1) in red and and for activated 
microglia/macrophagus (ED1) in green inside the biomaterial. Dapi was used to identify nuclei 








Figure 6. Quantification of microgial cell populations.  
A. The graph represents the cell density (nº cells/mm2) of microglial cells (Iba1+). B. The 
density of activated microglia/macrophagus cells (ED1+). C. Activated microglia (Iba1+ED1+). 
D. Infiltrated macrophages (Iba-ED1+). E. Resting microglia (Iba1+ED1-). Control: no injury or 
biomaterial, BM: biomaterial injured but untreated, BM+LA: injured, biomaterial and LA 
treatment. *p < 0.05, **p < 0.01, ***p < 0.001. 
  
Figure 7. Immature and mature neurons extend their axons inside the scaffold.  
Immunofluorescences for Tuj1 were done to identify immature neurons (red) and MAP2 
were done to identify mature neurons (green). Dapi was used to identify nuclei and biomaterial 
position. A. Axons extending form the surrounding tissue to the biomaterial. B. Immature 
neurons expressing marker of mature neurons. C. Mature neuron. D. Axons of mature neurons. 
White arrows indicate the axons within the biomaterial. Scale bars: 100 μm in A and B, 50 in C 
μm, 25 μm in D. E. Neuronal density (nº cells/mm2) inside the biomaterial of immature and 
mature neurons. Control: no injury or biomaterial, BM: biomaterial injured but untreated, 












Figure 8. Magnetic resonance imaging shows an improvement in tissue restoration 
inside the scaffold.  
Structural images T2 of untreated animals (A) and LA treated animals (B) were obtained 2 
months after the brain injury. C. Quantification in grey values of the tissue inside the 
biomaterial at 2 and 6 months. Scale bars: 2 mm. Control: no injury or biomaterial, BM: 







8. CAPTIONS  
 
